Lilly is committed to significantly improving individual patient outcomes. Understanding and responding to the range of diverse patient needs is one of the keys to realizing that vision. Lilly’s Clinical Diversity Strategy was created to better understand patient differences, which may affect clinical outcomes. Additionally, Lilly is working to increase the enrollment of racially and ethnically diverse populations in U.S. clinical trials.
In the past, fewer minority patients have participated in trials, which resulted in more limited information on the medicine’s safety and efficacy in those populations. The Clinical Diversity Strategy will help Lilly better understand the efficacy, side-effect profiles, and risks in minority populations — the fastest growing segment of the U.S. population.
Understanding the “face of the patient” is critical to Lilly’s tailored therapy approach: to deliver to patients the right medicine, at the right dose, at the right time.
- Earlier understanding of data to understand patient differences that may affect clinical outcomes.
- Increase enrollment of racially and ethnically diverse patients in clinical trials to better reflect disease prevalence.
- Collect, analyze, and disclose more specific demographic information in trials.